Pular para o conteúdo principal
Ranking Invest

AXSM - Axsome Therapeutics, Inc.

Segmento: HealthcareAxsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Análise Ranking Invest

Valuation estimado
-$ 761.90 Mi
Valor de Mercado
$ 11.56 Bi
Desconto (AV)-1617.7%
IVR
-0.07A companhia vale -0,07 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.07O valuation alternativo equivale a -7% do valor de mercado da companhia.
MLL
-0.07O lucro líquido dos controladores em 16 trimestres equivale a -7% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 83.30 Mi

Dívida Líquida

-$ 131.89 Mi

L4T

-$ 191.64 Mi

MM4T

-24.86%

Indicadores Básicos

ROE

-230.05%

Índices de Previsibilidade

Receita Líquida

E0.17

Lucro

B0.25

Margem

D0.99

Índices de Tendência

Receita Líquida

A11.38

Lucro

D1.03

Margem

A9.05

Índices de Endividamento

DIV/PAT

-1.58

DIV/L4T

0.69

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.